ELTX Profile
Elicio Therapeutics, Inc., a pioneering clinical-stage biotechnology firm, is focused on advancing a diverse portfolio of innovative immunotherapies aimed at treating cancer and other serious diseases. Based in Boston, Massachusetts, Elicio is dedicated to developing cutting-edge treatments through its proprietary AMP (Antigen Presentation Module) platform. This platform is designed to enhance the effectiveness of immunotherapies by improving antigen presentation and activating the immune system to target and destroy cancer cells.
The company’s lead product candidate, ELI-002, is an AMP therapeutic vaccine targeting KRAS-driven cancers, a challenging category of tumors associated with poor prognosis and limited treatment options. ELI-002 is designed to stimulate a robust immune response against KRAS mutations, which are prevalent in various cancers. In addition to ELI-002, Elicio is advancing several other candidates, including ELI-004, an AMP-modified CpG adjuvant that is a key component of ELI-002. This adjuvant is intended to enhance the vaccine's efficacy by boosting the immune response.
Elicio’s pipeline also includes ELI-007, a lymph node-targeted AMP-peptide vaccine aimed at cancers driven by mutant BRAF, and ELI-008, a multivalent version targeting mutant TP53-expressing cancers. These vaccines are designed to localize and intensify immune responses within lymph nodes, potentially increasing the precision and impact of treatment. Additionally, ELI-005 is being developed as a vaccine candidate for COVID-19 prevention, showcasing the company's versatility in addressing emerging health threats.
The company is also pursuing ELI-011 for the treatment of hematological cancers, which include blood cancers such as leukemia and lymphoma, and ELI-012, an mKRAS TCR T cell AMP-lifier intended to complement mKRAS-targeted TCR T cell therapies for cancers driven by KRAS mutations. Through these developments, Elicio aims to offer novel and effective therapeutic options across a broad range of cancers and other diseases, positioning itself at the forefront of immunotherapy innovation.
|
